Letrozole can cause twins, but the chance is relatively modest compared to other fertility medications. In the largest randomized trials, the twin rate among pregnancies conceived with letrozole has ranged from roughly 3 to 5 percent when the drug is used for standard ovulation induction, and up to about 13 percent when it is used more aggressively to stimulate multiple follicles. Those numbers sit well below what injectable fertility hormones produce, which is one reason letrozole has become a first-line treatment for many women struggling to conceive.
How Letrozole Prompts the Release of Extra Eggs
Letrozole belongs to a class of drugs called aromatase inhibitors. It works by blocking the enzyme responsible for the final step in estrogen production. When estrogen levels drop, your brain reads the dip as a signal that the ovaries need more stimulation, and it responds by ramping up the hormones that drive follicle growth. The result is that one or more follicles mature and release an egg during that cycle.
In a natural menstrual cycle, the body’s feedback loops usually ensure that only one follicle reaches maturity. Letrozole disrupts that balance just enough to push an extra follicle or two past the threshold. If two eggs release and both get fertilized, the outcome is fraternal twins. The drug does not cause identical twins; splitting of a single embryo is a separate, rare event that happens regardless of medication.
This mechanism also explains why letrozole’s twin risk is dose-dependent. A trial comparing 2.5 mg and 5 mg doses found that the higher dose produced significantly more follicles.1PubMed. A randomized trial of superovulation with two different doses of letrozole More follicles means more eggs in play, which means a higher chance of multiples. Clinicians typically start at the lower dose and step up only when a patient does not respond adequately.
What the Major Trials Actually Found
The twin rate with letrozole depends heavily on why the drug is being prescribed and how aggressively the ovaries are being stimulated. In clinical practice, the two most common scenarios are ovulation induction for women who are not ovulating on their own (often due to polycystic ovary syndrome) and superovulation for women with unexplained infertility. These scenarios produce meaningfully different twin rates.
The largest trial of letrozole in women with PCOS, published in the New England Journal of Medicine with over 750 participants, reported a twin pregnancy rate of about 3.4 percent in the letrozole group, compared to 7.4 percent with clomiphene.2PubMed Central. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome A separate study tracking congenital malformation rates in fertility treatment pregnancies recorded a twin rate of about 4.5 percent among letrozole-conceived pregnancies, versus roughly 6.4 percent with clomiphene.3PLOS ONE. Congenital Malformations among Babies Born Following Letrozole or Clomiphene for Infertility Treatment A trial of letrozole combined with metformin in clomiphene-resistant PCOS patients found twin pregnancies in a small fraction of cases as well.4PubMed Central. Pregnancies following the use of sequential treatment of metformin and incremental doses of letrozole in clomiphen-resistant women with polycystic ovary syndrome In a large Chinese trial of letrozole for PCOS, only one twin live birth occurred among 199 total live births in the letrozole group.5Fertility and Sterility. Randomized controlled trial of letrozole, berberine, or a combination for infertility in the polycystic ovary syndrome
When letrozole is used for superovulation, where the explicit goal is to develop multiple mature follicles, the picture changes. A large multicenter trial of women with unexplained infertility found a multiple gestation rate of about 13 percent among letrozole pregnancies, and every one of those multiples was twins rather than triplets.6PubMed Central. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility That 13 percent figure reflects a more aggressive treatment protocol than what most women on letrozole encounter. For someone taking letrozole simply to ovulate, the twin rate in well-designed trials clusters closer to that 3 to 5 percent range.
Letrozole Compared to Clomiphene and Injectable Hormones
Letrozole is often discussed alongside clomiphene (Clomid) because the two drugs fill a similar role as oral ovulation-induction agents. In head-to-head trials, letrozole consistently produces the same or slightly lower twin rates than clomiphene. The large PCOS trial found 3.4 percent versus 7.4 percent, and the trial comparing the two in unexplained infertility found 13 percent for letrozole versus 9 percent for clomiphene alone, a difference that was not statistically significant.6PubMed Central. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility In terms of overall pregnancy and live birth rates, the two drugs perform similarly for the general infertility population, while letrozole appears to have an edge in women with PCOS.7Human Reproduction. Emulating a target trial of the comparative effectiveness of clomiphene citrate and letrozole for ovulation induction
Injectable gonadotropins are a different story. These hormone injections stimulate the ovaries far more powerfully and produce substantially more follicles. In the unexplained infertility trial, the multiple gestation rate with gonadotropins alone reached about 32 percent, and those multiples included not just twins but triplet pregnancies as well.6PubMed Central. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility That is a striking contrast. An oral medication like letrozole gives the ovaries a nudge; injectable hormones turn the dial up much further. This is why fertility specialists often start with oral agents and reserve injectables for cases that do not respond.
One reason letrozole tends to produce fewer multiples than clomiphene has to do with how the drugs clear the body. Letrozole has a shorter half-life and does not accumulate in tissue the way clomiphene can. That means the suppression of estrogen is briefer, and the feedback mechanisms that normally select a single dominant follicle have a better chance of reasserting themselves before ovulation. The body gets a window of extra stimulation, but not a prolonged one.
Why the Number of Follicles Matters More Than the Drug Name
If you are trying to gauge your personal odds of twins on letrozole, the follicle count at the time of ovulation is the most useful piece of information. A woman who develops one mature follicle on letrozole has essentially the background rate of twins, which is about 1 to 2 percent in the general population. A woman who develops two or three mature follicles has a meaningfully higher chance, because each egg is an independent opportunity for fertilization.
This is why ultrasound monitoring during a letrozole cycle matters. Your doctor can see how many follicles are approaching maturity and make a call about whether to proceed with timed intercourse or intrauterine insemination that cycle. Current clinical recommendations advise aiming for one to two mature follicles in women who are being treated for anovulation (not ovulating on their own), and accepting multiple follicles only when the clinical strategy is intentional superovulation for patients with unexplained infertility or other specific indications.8Fertility and Sterility. Ovulation Induction and Superovulation If monitoring shows four or five mature follicles, the cycle may be canceled or converted to IVF to avoid a high-order multiple pregnancy.
A study looking at predictors of twin pregnancy after ovarian stimulation with intrauterine insemination found that the number of mature follicles was a key factor in whether multiples occurred.9PubMed. Predictors of twin pregnancy after ovarian stimulation and intrauterine insemination in women with unexplained infertility The medication matters, but what really drives the risk is how many targets are available when sperm arrives.
Why Doctors Try to Avoid Twin Pregnancies
Many people going through fertility treatment view twins as a welcome bonus. Research on patient attitudes has found that a majority of IVF patients actually prefer twins over singletons, citing the desire for siblings and the wish to go through fewer treatment cycles.10Human Reproduction. Patient attitudes towards twin pregnancies and single embryo transfer—a questionnaire study A separate survey found that while about 60 percent of female patients preferred a singleton, a substantial minority wanted multiples, and patients over 35 with longer infertility histories were less likely to change their minds even after learning about the risks.11PubMed Central. The Desire for Multiple Pregnancy among Patients with Infertility and Their Partners
Doctors, however, treat twin pregnancies as a complication to be minimized rather than a bonus to be celebrated. The reason is straightforward: twin pregnancies carry substantially higher rates of almost every adverse outcome compared to singletons. A large analysis of twin pregnancies after IVF found that the most common maternal complications included cesarean delivery in nearly 9 out of 10 cases, preterm birth in about 4 out of 10, gestational diabetes in roughly 1 in 5, and gestational hypertension or preeclampsia in close to 1 in 5.12JAMA Network Open. Absolute Risk of Adverse Obstetric Outcomes Among Twin Pregnancies After In Vitro Fertilization by Maternal Age
The risks are not limited to IVF-conceived twins. A study comparing twin pregnancies by conception method found that women who conceived twins through ovulation induction or intrauterine insemination had higher rates of unplanned hysterectomy, ICU admission, blood transfusion, and severe tears than women who conceived twins spontaneously.13PubMed. Neonatal and maternal outcomes among twin pregnancies stratified by mode of conception in the United States Another study found that subfertile women carrying twins faced roughly double the risk of uterine bleeding and placental complications compared to fertile women with twin pregnancies.14PubMed Central. Adverse pregnancy, birth, and infant outcomes in twins The underlying subfertility itself appears to compound the risks that twin pregnancy already carries.
For the babies, preterm birth is the biggest concern. Twins are far more likely to arrive early, and prematurity is the leading driver of complications in newborns: breathing difficulties, feeding problems, longer NICU stays, and in severe cases, lasting developmental effects. A single healthy pregnancy carried to term is simply a safer outcome for both mother and child than a twin pregnancy, regardless of how the pregnancy was conceived.
Letrozole’s Safety Profile for the Babies
An earlier concern about letrozole was whether it could cause birth defects. This worry traces back to a single conference presentation in 2005 that reported higher malformation rates in letrozole-conceived pregnancies. That preliminary report led to a temporary chill in letrozole prescribing in some countries, but the finding has not held up. Large randomized trials and meta-analyses conducted since then have found no increase in congenital anomalies, miscarriage, or adverse outcomes in babies conceived after letrozole use compared to clomiphene or natural conception.15PubMed Central. Letrozole at the Crossroads of Efficacy and Fetal Safety in Ovulation Induction: A Narrative Review One study examining birth outcomes specifically after letrozole-induced frozen embryo transfer cycles in women with PCOS found that preterm birth rates, perinatal death, and birthweight were comparable whether the cycle used letrozole or not, in both singletons and twins.16American Journal of Obstetrics and Gynecology. Letrozole-induced frozen embryo transfer cycles are associated with a lower risk of hypertensive disorders of pregnancy among women with polycystic ovary syndrome
The original safety scare is worth knowing about, though, because you may encounter it in online forums or older medical literature. The evidence accumulated over the past two decades has been reassuring. Letrozole is now widely recommended as a first-line ovulation induction agent for PCOS by major reproductive medicine societies. The drug leaves the body quickly, well before the embryo implants, which is part of why long-term fetal exposure was never a realistic concern. By the time a pregnancy is established, letrozole is gone.
When the Twin Risk Goes Up
Several factors can push your personal odds of twins on letrozole higher than the average trial figure:
- Higher doses: Moving from 2.5 mg to 5 mg or even 7.5 mg increases follicle development and, with it, the probability of releasing more than one egg.
- Superovulation protocols: If your doctor is deliberately stimulating multiple follicles (common in unexplained infertility treatment combined with insemination), the twin rate can approach 10 to 15 percent rather than the 3 to 5 percent seen in standard ovulation induction.
- Younger age: Younger ovaries are more responsive to stimulation and more likely to produce multiple mature follicles at any given dose.
- Higher ovarian reserve: Women with more resting follicles (higher antral follicle counts) tend to recruit more follicles during stimulation.
- Combined treatment: Adding injectable gonadotropins to letrozole, or pairing letrozole with insemination, can push the multiple pregnancy rate upward compared to letrozole with timed intercourse alone.
Conversely, a woman taking the standard 2.5 mg dose who develops just one dominant follicle on monitoring has very little added twin risk beyond what she would face without medication. The drug creates the opportunity for multiples, but it does not guarantee it.
The Psychology of Wanting Two at Once
The disconnect between patient hopes and medical recommendations around twins is one of the more fascinating tensions in fertility medicine. Reviews of patient attitude studies have found that many people going through infertility treatment genuinely want twins, often because it feels like an efficient resolution to years of emotional and financial strain.17PubMed. Attitudes towards single embryo transfer, twin and higher order pregnancies in patients undergoing infertility treatment: a review The logic is intuitive: if you have been trying for years, the idea of getting two babies from one pregnancy is appealing. It means fewer cycles, less time, less money, and an instant family.
What the research also shows, though, is that patient preferences shift when the actual risks become concrete. As success rates for fertility treatment have improved and evidence about twin pregnancy complications has accumulated, patients have become more receptive to strategies that minimize multiples. Younger patients and those with prior knowledge of twin pregnancy risks are especially likely to prefer singletons.11PubMed Central. The Desire for Multiple Pregnancy among Patients with Infertility and Their Partners Older patients with long infertility histories are harder to persuade, which makes sense: for them, the perceived cost of another failed cycle outweighs the statistical risk of a complicated twin pregnancy.
If you are on letrozole and privately hoping for twins, that is a completely normal feeling. Just know that your medical team is not withholding multiples out of overcaution. The risks to both you and the babies are well-documented and real. The goal of treatment, as reproductive medicine guidelines put it, is one healthy baby at a time. Twins happen sometimes anyway, and when they do, they can be managed well. But engineering a higher chance of twins by requesting unnecessary dose increases or skipping monitoring creates risk without proportional benefit.
What Letrozole Cannot Do
It is worth being clear about what letrozole is not. It is not a “fertility super drug” that dramatically multiplies your chances of pregnancy each cycle. In large comparative studies, the per-cycle pregnancy rate with letrozole is only modestly better than with clomiphene for the general infertility population, and letrozole’s main advantage in PCOS is a higher cumulative live birth rate over multiple cycles rather than a dramatically different result in any single cycle.7Human Reproduction. Emulating a target trial of the comparative effectiveness of clomiphene citrate and letrozole for ovulation induction Letrozole also does not bypass other barriers to conception like blocked tubes, severe male factor infertility, or uterine abnormalities. It helps you ovulate; it does not fix everything downstream of ovulation.
The drug is also not a long-term intervention. Most protocols involve taking letrozole for five days early in the menstrual cycle, with treatment typically spanning three to six cycles before the doctor reassesses the plan. If letrozole is not working after several well-monitored cycles, the next step usually involves injectable hormones, IVF, or both. Each escalation comes with a higher multiple pregnancy rate but also a higher per-cycle pregnancy rate, which is the tradeoff your doctor is managing at every stage.